Cargando…

Translating clinical trial results into personalized recommendations by considering multiple outcomes and subjective views

Currently, clinicians rely mostly on population-level treatment effects from RCTs, usually considering the treatment's benefits. This study proposes a process, focused on practical usability, for translating RCT data into personalized treatment recommendations that weighs benefits against harms...

Descripción completa

Detalles Bibliográficos
Autores principales: Dagan, Noa, Cohen-Stavi, Chandra J., Avgil Tsadok, Meytal, Leibowitz, Morton, Hoshen, Moshe, Karpati, Tomas, Akriv, Amichay, Gofer, Ilan, Gilutz, Harel, Podjarny, Eduardo, Bachmat, Eitan, Balicer, Ran D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704144/
https://www.ncbi.nlm.nih.gov/pubmed/31453376
http://dx.doi.org/10.1038/s41746-019-0156-3
_version_ 1783445448216805376
author Dagan, Noa
Cohen-Stavi, Chandra J.
Avgil Tsadok, Meytal
Leibowitz, Morton
Hoshen, Moshe
Karpati, Tomas
Akriv, Amichay
Gofer, Ilan
Gilutz, Harel
Podjarny, Eduardo
Bachmat, Eitan
Balicer, Ran D.
author_facet Dagan, Noa
Cohen-Stavi, Chandra J.
Avgil Tsadok, Meytal
Leibowitz, Morton
Hoshen, Moshe
Karpati, Tomas
Akriv, Amichay
Gofer, Ilan
Gilutz, Harel
Podjarny, Eduardo
Bachmat, Eitan
Balicer, Ran D.
author_sort Dagan, Noa
collection PubMed
description Currently, clinicians rely mostly on population-level treatment effects from RCTs, usually considering the treatment's benefits. This study proposes a process, focused on practical usability, for translating RCT data into personalized treatment recommendations that weighs benefits against harms and integrates subjective perceptions of relative severity. Intensive blood pressure treatment (IBPT) was selected as the test case to demonstrate the suggested process, which was divided into three phases: (1) Prediction models were developed using the Systolic Blood-Pressure Intervention Trial (SPRINT) data for benefits and adverse events of IBPT. The models were externally validated using retrospective Clalit Health Services (CHS) data; (2) Predicted risk reductions and increases from these models were used to create a yes/no IBPT recommendation by calculating a severity-weighted benefit-to-harm ratio; (3) Analysis outputs were summarized in a decision support tool. Based on the individual benefit-to-harm ratios, 62 and 84% of the SPRINT and CHS populations, respectively, would theoretically be recommended IBPT. The original SPRINT trial results of significant decrease in cardiovascular outcomes following IBPT persisted only in the group that received a “yes-treatment” recommendation by the suggested process, while the rate of serious adverse events was slightly higher in the "no-treatment" recommendation group. This process can be used to translate RCT data into individualized recommendations by identifying patients for whom the treatment’s benefits outweigh the harms, while considering subjective views of perceived severity of the different outcomes. The proposed approach emphasizes clinical practicality by mimicking physicians’ clinical decision-making process and integrating all recommendation outputs into a usable decision support tool.
format Online
Article
Text
id pubmed-6704144
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-67041442019-08-26 Translating clinical trial results into personalized recommendations by considering multiple outcomes and subjective views Dagan, Noa Cohen-Stavi, Chandra J. Avgil Tsadok, Meytal Leibowitz, Morton Hoshen, Moshe Karpati, Tomas Akriv, Amichay Gofer, Ilan Gilutz, Harel Podjarny, Eduardo Bachmat, Eitan Balicer, Ran D. NPJ Digit Med Article Currently, clinicians rely mostly on population-level treatment effects from RCTs, usually considering the treatment's benefits. This study proposes a process, focused on practical usability, for translating RCT data into personalized treatment recommendations that weighs benefits against harms and integrates subjective perceptions of relative severity. Intensive blood pressure treatment (IBPT) was selected as the test case to demonstrate the suggested process, which was divided into three phases: (1) Prediction models were developed using the Systolic Blood-Pressure Intervention Trial (SPRINT) data for benefits and adverse events of IBPT. The models were externally validated using retrospective Clalit Health Services (CHS) data; (2) Predicted risk reductions and increases from these models were used to create a yes/no IBPT recommendation by calculating a severity-weighted benefit-to-harm ratio; (3) Analysis outputs were summarized in a decision support tool. Based on the individual benefit-to-harm ratios, 62 and 84% of the SPRINT and CHS populations, respectively, would theoretically be recommended IBPT. The original SPRINT trial results of significant decrease in cardiovascular outcomes following IBPT persisted only in the group that received a “yes-treatment” recommendation by the suggested process, while the rate of serious adverse events was slightly higher in the "no-treatment" recommendation group. This process can be used to translate RCT data into individualized recommendations by identifying patients for whom the treatment’s benefits outweigh the harms, while considering subjective views of perceived severity of the different outcomes. The proposed approach emphasizes clinical practicality by mimicking physicians’ clinical decision-making process and integrating all recommendation outputs into a usable decision support tool. Nature Publishing Group UK 2019-08-21 /pmc/articles/PMC6704144/ /pubmed/31453376 http://dx.doi.org/10.1038/s41746-019-0156-3 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Dagan, Noa
Cohen-Stavi, Chandra J.
Avgil Tsadok, Meytal
Leibowitz, Morton
Hoshen, Moshe
Karpati, Tomas
Akriv, Amichay
Gofer, Ilan
Gilutz, Harel
Podjarny, Eduardo
Bachmat, Eitan
Balicer, Ran D.
Translating clinical trial results into personalized recommendations by considering multiple outcomes and subjective views
title Translating clinical trial results into personalized recommendations by considering multiple outcomes and subjective views
title_full Translating clinical trial results into personalized recommendations by considering multiple outcomes and subjective views
title_fullStr Translating clinical trial results into personalized recommendations by considering multiple outcomes and subjective views
title_full_unstemmed Translating clinical trial results into personalized recommendations by considering multiple outcomes and subjective views
title_short Translating clinical trial results into personalized recommendations by considering multiple outcomes and subjective views
title_sort translating clinical trial results into personalized recommendations by considering multiple outcomes and subjective views
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704144/
https://www.ncbi.nlm.nih.gov/pubmed/31453376
http://dx.doi.org/10.1038/s41746-019-0156-3
work_keys_str_mv AT dagannoa translatingclinicaltrialresultsintopersonalizedrecommendationsbyconsideringmultipleoutcomesandsubjectiveviews
AT cohenstavichandraj translatingclinicaltrialresultsintopersonalizedrecommendationsbyconsideringmultipleoutcomesandsubjectiveviews
AT avgiltsadokmeytal translatingclinicaltrialresultsintopersonalizedrecommendationsbyconsideringmultipleoutcomesandsubjectiveviews
AT leibowitzmorton translatingclinicaltrialresultsintopersonalizedrecommendationsbyconsideringmultipleoutcomesandsubjectiveviews
AT hoshenmoshe translatingclinicaltrialresultsintopersonalizedrecommendationsbyconsideringmultipleoutcomesandsubjectiveviews
AT karpatitomas translatingclinicaltrialresultsintopersonalizedrecommendationsbyconsideringmultipleoutcomesandsubjectiveviews
AT akrivamichay translatingclinicaltrialresultsintopersonalizedrecommendationsbyconsideringmultipleoutcomesandsubjectiveviews
AT goferilan translatingclinicaltrialresultsintopersonalizedrecommendationsbyconsideringmultipleoutcomesandsubjectiveviews
AT gilutzharel translatingclinicaltrialresultsintopersonalizedrecommendationsbyconsideringmultipleoutcomesandsubjectiveviews
AT podjarnyeduardo translatingclinicaltrialresultsintopersonalizedrecommendationsbyconsideringmultipleoutcomesandsubjectiveviews
AT bachmateitan translatingclinicaltrialresultsintopersonalizedrecommendationsbyconsideringmultipleoutcomesandsubjectiveviews
AT balicerrand translatingclinicaltrialresultsintopersonalizedrecommendationsbyconsideringmultipleoutcomesandsubjectiveviews